CDSCO Cautions Pharma Firms Against Promoting Anti-Obesity Drugs As Companies Compete For A Share Of Booming Market

As pharmaceutical companies intensify competition to capture a share of the fast-growing anti-obesity drug market, India’s drug regulator has cautioned firms against engaging in direct or indirect promotional campaigns for prescription medicines used to treat obesity and metabolic disorders.

The advisory issued by the Central Drugs Standard Control Organisation (CDSCO) comes at a time when demand for new-generation weight-loss drugs is rising sharply worldwide and in India, prompting aggressive commercial strategies by pharma firms seeking to establish dominance in the emerging market.

Drugs belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class—originally developed for diabetes management—are increasingly being prescribed for weight reduction. Their growing popularity has triggered intense competition among global and domestic drugmakers aiming to expand their presence in the obesity treatment segment.

Against this backdrop, the regulator has warned manufacturers, importers, and marketing authorization holders against any form of promotional activity targeting the general public. This includes direct advertisements as well as indirect or surrogate campaigns that may create visibility for prescription medicines.

The advisory follows observations by the Directorate General of Health Services (DGHS), under which CDSCO functions, that certain pharmaceutical companies may be engaging in indirect promotional strategies linked to anti-obesity drugs. These activities include disease-awareness campaigns, digital media outreach, and other communication efforts related to GLP-1 receptor agonists and similar therapies.

Officials noted that such initiatives may effectively function as surrogate advertisements, indirectly encouraging public demand for prescription medicines.

“Any promotional activity, including so-called disease awareness campaigns, that functions as a surrogate advertisement for prescription-only drugs shall be viewed seriously,” the regulator said in the advisory.

Prescription medicines—including GLP-1 receptor agonists used in the treatment of obesity and metabolic disorders—must be prescribed only by registered medical practitioners or specialists in accordance with approved indications and conditions of marketing authorization, CDSCO clarified.

Under existing regulations, the promotion of prescription-only medicines directly to consumers is prohibited. The regulator warned that advertisements that exaggerate therapeutic benefits, promise guaranteed weight-loss outcomes, or downplay the importance of lifestyle modification could be treated as misleading promotion.

“Any form of advertisement that promotes prescription-only medicines to the general public, exaggerates therapeutic efficacy, suggests assured weight-loss outcomes, or undermines lifestyle interventions such as diet control, exercise, and behavioral changes may attract regulatory action,” the advisory said.

Public health authorities emphasized that obesity is a chronic metabolic condition requiring comprehensive management. Pharmacological treatment, where medically indicated, should be viewed as only one component of therapy and not as a replacement for lifestyle-based interventions.

Experts have repeatedly warned that portraying weight-loss drugs as quick solutions could distort public understanding of obesity management, especially in countries like India where lifestyle-related diseases are rising rapidly.

The regulator also cautioned pharmaceutical companies against using indirect promotional tools such as social media influencers, corporate campaigns, or public engagement programs that create brand recall for prescription drugs.

According to the advisory, any promotional activity carried out under the pretext of disease awareness, influencer engagement, or corporate communication that generates product visibility or brand recall would be treated as a violation of regulatory provisions.

The prohibition on promotional activity applies across all public platforms, including print, television, digital media, and social media channels.

To strengthen accountability and transparency, CDSCO has also directed companies to ensure that product information sheets and patient information leaflets prominently display details of authorized personnel and official office codes. Manufacturers must also provide dedicated contact numbers along with complaint or ticket-reference mechanisms to address consumer queries and facilitate reporting of concerns.

Additionally, companies marketing such medicines will be required to submit a comprehensive risk management plan to the regulator. This plan must outline continued safety monitoring as well as appropriate risk-minimization measures associated with the use of these drugs.

The CDSCO reiterated that all manufacturers and marketing authorization holders must strictly comply with provisions of the Drugs and Cosmetics Act, 1940, and the accompanying Drugs Rules, 1945. These laws require that the manufacture, sale, distribution, and promotion of medicines adhere strictly to approved indications, labeling requirements, and statutory conditions.

The regulator also emphasized the need for ethical marketing practices to ensure that vulnerable populations are not misled or exploited through exaggerated claims or promotional messaging.